GlassScriptPhysician profile
Tonya Mae Fraser
NPI 1508839226
$15,541.16
in general payments reported to CMS, 2019-2025
63 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,641 · 2022: $2,900 · 2023: $3,518 · 2024: $3,286 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,999.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,352.09 | 2021-2025 | |
| Novo Nordisk INC | $1,859.34 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,635.55 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $922.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $908.26 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.18 | 2021-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $629.95 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $577.58 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $540.31 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $389.38 | 2021-2025 | Repatha, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $370.27 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $324.41 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.34 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $270.12 | 2021-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $236.94 | 2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.